Journal
JOURNAL OF CLINICAL ONCOLOGY
Volume 23, Issue 34, Pages 8588-8596Publisher
AMER SOC CLINICAL ONCOLOGY
DOI: 10.1200/JCO.2004.00.5355
Keywords
-
Categories
Funding
- NINDS NIH HHS [NS33618, NS44687, NS34608] Funding Source: Medline
Ask authors/readers for more resources
Purpose To describe the frequency and severity of ototoxicity in a series of pediatric patients treated with platinum-based chemotherapy. Patients and Methods Serial audiologic evaluations were conducted for 67 patients aged 8 months to 23 years who received platinum-based chemotherapy. Audiologic data was analyzed to determine time to hearing-loss using American Speech-Language-Hearing Association (ASHA) criteria, and the effects of treatment and patient characteristics on the incidence and severity of ototoxicity. Results Bilateral decreases in hearing were seen in 61 % of patients (median time to hearing loss, 135 days). Children treated for medulloblastoma, osteosarcoma, and neuroblastoma had greater incidence and severity of hearing loss. Agreement between the usually reported National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) and ASHA criteria was inadequate. Conclusion Traditional reporting of toxicity data (CTCAE) has tinder-reported ototoxicity and minimized the significance of hearing loss in children. As pediatric patients experience improved survival, the effects and implications of high-frequency hearing loss with regard to academic achievement and speech and language development are important considerations, especially in patients younger than 5 years.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available